This slide show highlights the 2014 FDA approvals of cancer treatments, which included therapies for melanoma and lung, gastric, ovarian, and cervical cancers, as well as various hematologic malignancies.
Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC
October 4th 2023Investigators will present overall survival and objective response data from the phase 3 MARIPOSA trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.
2 Clarke Drive
Cranbury, NJ 08512